Why does viral load measurement matter for target validation?

Periodic assessment of HIV-1 infection suppression confirms whether oral cART effectively inhibits viral replication in vivo. This measurement provides a direct readout of target engagement by reverse transcriptase and integrase inhibitors. Sustained reduction in viral load supports mechanistic de-risking of the therapeutic hypothesis.

How does isolating the independent variable of drug composition support the discovery pipeline?

By preparing defined mixtures of FTC, TDF, and integrase inhibitors, the study isolates the effect of specific drug combinations on viral suppression. This enables clear attribution of observed outcomes to the pharmacological activity of the administered compounds. Isolating the independent variable strengthens causal inference in target validation efforts.

What do quantitative dependent variable measurements enable in this assay?

Quantitative assessments of HIV-1 suppression allow comparison of different cART formulations over time. These measurements generate dose-response and time-course data essential for evaluating therapeutic efficacy. Such outputs support lead identification by ranking candidates based on measurable antiviral activity.

Why do replication requirements matter for cross-functional collaboration?

Regularly refreshing cART food three times per week ensures consistent drug exposure across study replicates. This standardization allows virology, pharmacology, and animal care teams to rely on reproducible results. Reproducible outcomes build confidence in data sharing and joint decision-making across functions.

What statistical analysis capabilities are required before implementing this model?

Teams must be able to analyze longitudinal viral load data to determine significant suppression relative to controls. Capabilities in comparing group means across time points are essential for interpreting treatment effects. These analytical skills enable objective go/no-go assessments based on predefined efficacy thresholds.

Oral Combinational Antiretroviral Therapy to Treat HIV-1 Infection in a Humanized Mouse Model

JoVE Encyclopedia of Experiments

Immunology

0 views • 4:19 min • July 8th, 2025

$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

Take a mixture of drugs targeting the human immunodeficiency virus-1, or HIV-1, for an oral combinational antiretroviral therapy, or oral cART.

Combine the mixture with a nutritional supplement containing a moderate fat content to facilitate drug absorption in the body.

Introduce antibiotics to prevent opportunistic infections in the HIV-1-infected mouse model, possessing engrafted human immune cells.

Upon consumption of the mixture, the drugs enter the HIV-1-infected cells carrying the viral RNA genome and enzymes.

A subset of drugs, termed reverse transcriptase inhibitors, mimics natural deoxyribonucleotides.

When the viral RNA undergoes reverse transcription, the inhibitors are incorporated into the growing DNA chain, inhibiting the reverse transcriptase and terminating viral DNA synthesis.

The other subset, termed integrase strand transfer inhibitors, inhibits viral integrase, preventing the integration of reverse-transcribed DNA into the host genome and ceasing viral replication.

Periodically assess the mouse for HIV-1 infection suppression, confirming the success of oral cART.

Begin by weighing individual drugs. Make 10 food cups with cART using sterile cell scrapers to weigh out 250 milligrams of FTC, 375 milligrams of TDF, and 500 milligrams of RAL or ELV into individual sterile 50-milliliter centrifuge tubes in a biosafety cabinet. Add DMSO to the FTC and TDF tube to make up a final concentration of 250 milligrams per milliliter, and into the ERL or ELV tube to a final concentration of 500 milligrams per milliliter.

Mix the drug solution by stirring and pipetting until a clear solution is obtained. Sterilize the solutions using a 0.22-micrometer hydrophilic PVDF membrane filter with a sterile syringe. Individual drug solutions can be stored at minus 20 degrees Celsius for 12 weeks.

Freshly thaw one aliquot of each drug solution before use at 37 degrees Celsius until the solution becomes clear. Mix well using a pipette. Combine the drugs dissolved in DMSO, and mix well to make up a master mix containing one milliliter of FTC, 1.5 milliliters of TDF, and 1 milliliter of ELV or RAL.

Add 350 microliters of cART master mixed solution into a to prepare one diet gel boost cART cup. Add 0.75 milliliters of trimethoprim-sulfamethoxazole into the cup. Stir thoroughly using 1-milliliter sterile pipette tips. Using a pipette tip, aliquot the food containing cART onto a 60-millimeter Petri dish.

Calculate the amount of cART in the food cup by weighing the food for each cage according to the number of mice. Remove regular chow from the cage, and replace it with a food cup containing cART. Refresh cART food three times per week. Weigh used cups to monitor intake. Then weigh the mice weekly to confirm consumption.